Developer docs
API playgroundTry for free, no card

Search company profiles

VBL Therapeutics

Full company profile

uuid0005j5i

Namestring
VBL Therapeutics
Legal namestring
Vascular Biogenics Ltd.
Websiteurl
vblrx.com
Company typeenum
Public
Founded yearint
2000
Descriptiontext

VBL Therapeutics (Nasdaq: VBLT), legally Vascular Biogenics Ltd. operating as VBL Therapeutics, Inc., is a clinical-stage biopharmaceutical company founded in 2000 by Prof. Dror Harats, M.D. and headquartered in Modi'in, Israel with a U.S. office in Pearl River, NY. The company is pre-revenue with no FDA-approved or commercially marketed products and no NDA submitted; all products are either in pre-clinical research or administered under IND applications in clinical trials. The company is led by a founder-CEO with 200+ peer-reviewed publications and a refreshed board and management team, and has raised over $180M in equity and non-dilutive capital since inception.

The company's core technology is a proprietary Monocyte Targeting Technology (MTT) platform built around the discovery of MOSPD2, a receptor selectively expressed on the surface of monocytes that controls their ability to migrate to inflamed tissues. The lead clinical candidate, VB-601, is an investigational monoclonal antibody that binds the MOSPD2 ("mono-walk") receptor and arrests monocyte migration, addressing chronic inflammation via a mechanism distinct from prevailing T-cell and B-cell-targeted anti-inflammatory biologics. VB-601 has shown disease-modifying activity in preclinical models across multiple sclerosis, rheumatoid arthritis, psoriatic arthritis, NASH, and inflammatory bowel disease, with a first-in-human Phase 1 study planned for Q1 2023. The company's earlier oncology asset, ofra-vec (VB-111), is a gene-therapy candidate that was in Phase 3 development for ovarian cancer with topline data expected in H2 2022 and was supported by a €17.5M EIC Accelerator award in December 2021.

VBL's business model is currently pre-commercial. There are no marketed products, no product pricing, no commercial distribution channels, and no recurring revenue. Distribution is limited to investigational use under clinical trial protocols. Future revenue, if any, would derive from one-time or recurring drug commercialization sales, licensing royalties, or partnership milestone payments contingent on regulatory approval — none of which has been secured. Stakeholder engagement is conducted via a corporate website (vblrx.com), a dedicated investor relations microsite (ir.vblrx.com), email/phone contact channels for business development and IR, and peer-reviewed scientific publications supporting the MTT platform. The customer base, once a product is approved, would consist of patients with immune-inflammatory diseases, prescribing physicians, and potentially large-pharma partners for licensing or co-development.

Short descriptiontext

VBL Therapeutics (Nasdaq: VBLT) is a clinical-stage biopharmaceutical company developing targeted antibody therapies for immune-inflammatory diseases using its proprietary Monocyte Targeting Technology (MTT) platform built around the novel MOSPD2 receptor on monocytes, with lead candidate VB-601 entering Phase 1 in Q1 2023.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersOr Yehuda, Israel
HQ citystring
Or Yehuda
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage biopharmaceuticals, monoclonal antibody therapies, immune-inflammatory disease treatments, monocyte targeting technology, investigational oncology therapeutics
Industry3 codes
PRIMARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biopharmaceuticals / Immunology Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1None (pre-revenue, clinical-stage)
TypeLicensing Royalties
Description

VBL Therapeutics is pre-revenue with no approved products. None of VBL's products have yet been approved for marketing by the U.S. FDA or other foreign regulatory agencies, and no NDA or equivalent has been submitted. Revenue generation is not currently active; future revenue streams would derive from drug commercialization (one-time/recurring sales), licensing royalties, or partnership/milestone payments post-approval.

vblrx.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

VBL Therapeutics is a clinical-stage biopharmaceutical company developing targeted antibody therapies for immune-inflammatory diseases through its proprietary Monocyte Targeting Technology (MTT) platform, which targets the MOSPD2 receptor on monocytes to block their migration into inflamed tissues. Its lead candidate VB-601 is an investigational monoclonal antibody intended for multiple sclerosis, rheumatoid arthritis, psoriatic arthritis, NASH and inflammatory bowel disease. The company has no FDA-approved or commercially marketed products and is pre-revenue.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • VB-601 shown disease-modifying activity across multiple preclinical models including multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease
Product overview1 text field

VBL Therapeutics operates a single-therapeutic-area pipeline anchored by one proprietary platform, Monocyte Targeting Technology (MTT), rather than a multi-module software platform. The MTT platform — built around the MOSPD2 'mono-walk' receptor on monocytes — generates targeted antibody candidates for chronic immune-inflammatory diseases, and its sole clinical-stage output is the lead candidate VB-601, an investigational anti-MOSPD2 monoclonal antibody in development for multiple sclerosis, rheumatoid arthritis, psoriatic arthritis, NASH, and inflammatory bowel disease, with a first-in-human Phase 1 study planned for Q1 2023. The company's earlier oncology asset, ofra-vec (VB-111), was a separate gene-therapy product candidate for ovarian cancer in Phase 3 development through 2021–2022, supported by EIC Accelerator funding. No commercialized products, software modules, or SaaS components are offered; the offering is therefore a platform-plus-lead-asset structure rather than a unified marketed product.

Product and service3 records
1VB-601
CategoryLead immunology product candidate (investigational monoclonal antibody)
Description

VB-601 is VBL Therapeutics' lead immunology product candidate — an investigational proprietary monoclonal antibody that binds the MOSPD2 ("mono-walk") receptor on monocytes to block their migration into inflamed tissues. It has shown disease-modifying activity in preclinical models across multiple sclerosis, rheumatoid arthritis, psoriatic arthritis, NASH, and inflammatory bowel disease, and was expected to enter a first-in-human Phase 1 study in Q1 2023.

2Monocyte Targeting Technology (MTT) platform
CategoryProprietary drug-discovery platform / target engine
Description

MTT is VBL's proprietary platform technology built around the discovery of the MOSPD2 receptor selectively expressed on the surface of monocytes that controls their ability to migrate to inflamed tissues. VB-601 is the lead candidate emerging from this platform, and MTT underpins VBL's pipeline of targeted antibody therapies for chronic immune-inflammatory diseases.

3ofra-vec (VB-111)
CategoryPrior clinical-stage oncology product candidate
Description

ofra-vec (VB-111) is VBL Therapeutics' cancer treatment candidate that was being evaluated in a Phase 3 ovarian cancer clinical trial with topline data expected in the second half of 2022. It received €17.5 million in EIC Accelerator funding (€2.5M grant + €15M equity) in December 2021 to support clinical development and pre-commercialization.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat2 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

VBL Therapeutics

Biopharmaceuticals / Immunology Therapeuticsvblrx.com

VBL Therapeutics (Nasdaq: VBLT) is a clinical-stage biopharmaceutical company developing targeted antibody therapies for immune-inflammatory diseases using its proprietary Monocyte Targeting Technology (MTT) platform built around the novel MOSPD2 receptor on monocytes, with lead candidate VB-601 entering Phase 1 in Q1 2023.

What VBL Therapeutics does

VBL Therapeutics (Nasdaq: VBLT), legally Vascular Biogenics Ltd. operating as VBL Therapeutics, Inc., is a clinical-stage biopharmaceutical company founded in 2000 by Prof. Dror Harats, M.D. and headquartered in Modi'in, Israel with a U.S. office in Pearl River, NY. The company is pre-revenue with no FDA-approved or commercially marketed products and no NDA submitted; all products are either in pre-clinical research or administered under IND applications in clinical trials. The company is led by a founder-CEO with 200+ peer-reviewed publications and a refreshed board and management team, and has raised over $180M in equity and non-dilutive capital since inception.

The company's core technology is a proprietary Monocyte Targeting Technology (MTT) platform built around the discovery of MOSPD2, a receptor selectively expressed on the surface of monocytes that controls their ability to migrate to inflamed tissues. The lead clinical candidate, VB-601, is an investigational monoclonal antibody that binds the MOSPD2 ("mono-walk") receptor and arrests monocyte migration, addressing chronic inflammation via a mechanism distinct from prevailing T-cell and B-cell-targeted anti-inflammatory biologics. VB-601 has shown disease-modifying activity in preclinical models across multiple sclerosis, rheumatoid arthritis, psoriatic arthritis, NASH, and inflammatory bowel disease, with a first-in-human Phase 1 study planned for Q1 2023. The company's earlier oncology asset, ofra-vec (VB-111), is a gene-therapy candidate that was in Phase 3 development for ovarian cancer with topline data expected in H2 2022 and was supported by a €17.5M EIC Accelerator award in December 2021.

VBL's business model is currently pre-commercial. There are no marketed products, no product pricing, no commercial distribution channels, and no recurring revenue. Distribution is limited to investigational use under clinical trial protocols. Future revenue, if any, would derive from one-time or recurring drug commercialization sales, licensing royalties, or partnership milestone payments contingent on regulatory approval — none of which has been secured. Stakeholder engagement is conducted via a corporate website (vblrx.com), a dedicated investor relations microsite (ir.vblrx.com), email/phone contact channels for business development and IR, and peer-reviewed scientific publications supporting the MTT platform. The customer base, once a product is approved, would consist of patients with immune-inflammatory diseases, prescribing physicians, and potentially large-pharma partners for licensing or co-development.

VBL Therapeutics firmographics

Firmographics
Name
VBL Therapeutics
Legal name
Vascular Biogenics Ltd.
Website
https://vblrx.com
Company type
Public
Founded year
2000
Operating status
Operating
Headcount range
11–50 employees
Short description
VBL Therapeutics (Nasdaq: VBLT) is a clinical-stage biopharmaceutical company developing targeted antibody therapies for immune-inflammatory diseases using its proprietary Monocyte Targeting Technology (MTT) platform built around the novel MOSPD2 receptor on monocytes, with lead candidate VB-601 entering Phase 1 in Q1 2023.
Ownership category
akta.pro rank

VBL Therapeutics industry classification

Industry
Product category
Biopharmaceuticals / Immunology Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Clinical-stage biopharmaceuticals
  • Monoclonal antibody therapies
  • Immune-inflammatory disease treatments
  • Monocyte targeting technology
  • Investigational oncology therapeutics

Where VBL Therapeutics is headquartered

Location

Headquarters

HQ city
Or Yehuda
HQ country
Israel
HQ region
Middle East

Offices2 records

Markets served

VBL Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. None (pre-revenue, clinical-stage): VBL Therapeutics is pre-revenue with no approved products. None of VBL's products have yet been approved for marketing by the U.S. FDA or other foreign regulatory agencies, and no NDA or equivalent has been submitted. Revenue generation is not currently active; future revenue streams would derive from drug commercialization (one-time/recurring sales), licensing royalties, or partnership/milestone payments post-approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

VBL Therapeutics product offering

Product offering

Core offering

VBL Therapeutics is a clinical-stage biopharmaceutical company developing targeted antibody therapies for immune-inflammatory diseases through its proprietary Monocyte Targeting Technology (MTT) platform, which targets the MOSPD2 receptor on monocytes to block their migration into inflamed tissues. Its lead candidate VB-601 is an investigational monoclonal antibody intended for multiple sclerosis, rheumatoid arthritis, psoriatic arthritis, NASH and inflammatory bowel disease. The company has no FDA-approved or commercially marketed products and is pre-revenue.

Product overview

VBL Therapeutics operates a single-therapeutic-area pipeline anchored by one proprietary platform, Monocyte Targeting Technology (MTT), rather than a multi-module software platform. The MTT platform — built around the MOSPD2 'mono-walk' receptor on monocytes — generates targeted antibody candidates for chronic immune-inflammatory diseases, and its sole clinical-stage output is the lead candidate VB-601, an investigational anti-MOSPD2 monoclonal antibody in development for multiple sclerosis, rheumatoid arthritis, psoriatic arthritis, NASH, and inflammatory bowel disease, with a first-in-human Phase 1 study planned for Q1 2023. The company's earlier oncology asset, ofra-vec (VB-111), was a separate gene-therapy product candidate for ovarian cancer in Phase 3 development through 2021–2022, supported by EIC Accelerator funding. No commercialized products, software modules, or SaaS components are offered; the offering is therefore a platform-plus-lead-asset structure rather than a unified marketed product.

Differentiator

Problem solved

Functional benefit

Products and services

  • VB-601 VB-601 is VBL Therapeutics' lead immunology product candidate — an investigational proprietary monoclonal antibody that binds the MOSPD2 ("mono-walk") receptor on monocytes to block their migration into inflamed tissues. It has shown disease-modifying activity in preclinical models across multiple sclerosis, rheumatoid arthritis, psoriatic arthritis, NASH, and inflammatory bowel disease, and was expected to enter a first-in-human Phase 1 study in Q1 2023.
  • Monocyte Targeting Technology (MTT) platform MTT is VBL's proprietary platform technology built around the discovery of the MOSPD2 receptor selectively expressed on the surface of monocytes that controls their ability to migrate to inflamed tissues. VB-601 is the lead candidate emerging from this platform, and MTT underpins VBL's pipeline of targeted antibody therapies for chronic immune-inflammatory diseases.
  • ofra-vec (VB-111) ofra-vec (VB-111) is VBL Therapeutics' cancer treatment candidate that was being evaluated in a Phase 3 ovarian cancer clinical trial with topline data expected in the second half of 2022. It received €17.5 million in EIC Accelerator funding (€2.5M grant + €15M equity) in December 2021 to support clinical development and pre-commercialization.

Quantifiable outcome

  • VB-601 shown disease-modifying activity across multiple preclinical models including multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease

Companies that use VBL Therapeutics

Customer profile

Segments3 records

Ideal customer profiles3 records

VBL Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

VBL Therapeutics partnerships and signals

Strategic signal

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

VBL Therapeutics competitors and assessment

Company assessment

Market position

Competitive moat2 records

Key risks6 records

Key highlights6 records

Customer concentration

VBL Therapeutics social profiles

Digital presence

VBL Therapeutics compliance and trust

Trust signal

Compliance4 records

VBL Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

VBL Therapeutics leadership team

Management profile

Number of profiles

Profiles9 records

VBL Therapeutics funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

VBL Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VBL Therapeutics

What does VBL Therapeutics do?

VBL Therapeutics is a clinical-stage biopharmaceutical company developing targeted antibody therapies for immune-inflammatory diseases through its proprietary Monocyte Targeting Technology (MTT) platform, which targets the MOSPD2 receptor on monocytes to block their migration into inflamed tissues. Its lead candidate VB-601 is an investigational monoclonal antibody intended for multiple sclerosis, rheumatoid arthritis, psoriatic arthritis, NASH and inflammatory bowel disease. The company has no FDA-approved or commercially marketed products and is pre-revenue.

Is VBL Therapeutics a public or private company?

VBL Therapeutics is a public company. It is classified as public and is currently operating.

When was VBL Therapeutics founded?

VBL Therapeutics was founded in 2000. It employs 11 to 50 people.

Where is VBL Therapeutics based?

VBL Therapeutics is headquartered in Or Yehuda, Israel, in the Middle East region.

How does VBL Therapeutics make money?

One revenue line is on record: none (pre-revenue, clinical-stage).

Does VBL Therapeutics have an API?

No public API is recorded for VBL Therapeutics.

What industry is VBL Therapeutics in?

VBL Therapeutics's product category is Biopharmaceuticals / Immunology Therapeutics. Its primary akta.pro industry code is HLAIAAAD, Immunology & Inflammation Pharmaceuticals, with a secondary code of HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AETOSWireAleph Farms Increases Production Capabilities with VBL Therapeutics Facility Acquisition and ESCO Aster PartnershipAleph Farms acquired a manufacturing facility in Modi'in, Israel, from VBL Therapeutics and signed an MOU with ESCO Aster to produce cultivated meat in Singapore. The agreements aim to increase production capabilities ahead of commercialization, with plans for additional strategic assets worldwide.GlobeNewswireNotable Labs Announces Filing of Form 10-Q for Third Quarter 2023Notable Labs filed its Form 10-Q for the third quarter and nine months ended September 30, 2023, containing pre-merger VBL Therapeutics financials. The company closed its merger with VBL in October and has $14.3 million in cash as of October 31, 2023. Pro forma combined financials will be provided via Form 8-K later in November.TradingViewNotable Labs Closes Merger Transaction With VBL TherapeuticsNotable Labs completed its merger with VBL Therapeutics, with shares trading on Nasdaq under 'NTBL' on October 17. The combined company raised $10.3 million in private placement and expects to fund operations into 2025. It will focus on developing Volasertib for AML in PPMP-predicted responders.YahooNotable Labs Closes Merger Transaction With VBL TherapeuticsNotable Labs completed its merger with VBL Therapeutics, with shares trading under 'NTBL' on Nasdaq Capital Market starting October 17, 2023. The combined company raised $10.3 million in private placement and expects to fund operations through 2025. It will focus on developing Volasertib for AML in platform-predicted responders.GlobeNewswireNotable Labs Closes Merger Transaction With VBL TherapeuticsNotable Labs completed its merger with VBL Therapeutics, with shares trading under 'NTBL' on Nasdaq Capital Market starting October 17, 2023. The combined company raised $10.3 million in private placement and expects to fund operations into 2025. It will focus on developing Volasertib for AML in platform-predicted responders.BioSpaceNotable Labs Closes Merger Transaction With VBL TherapeuticsNotable Labs completed its merger transaction with VBL Therapeutics, resulting in a combined entity that will trade on the Nasdaq under the ticker symbol "NTBL" starting October 17. The deal included a $10.3 million private placement led by investors such as Builders VC and Founders Fund, providing capital to fund operations through 2025. The merged company will focus on advancing Notable's Predictive Precision Medicines Platform and its lead asset Volasertib for acute myeloid leukemia.GlobeNewswireVBL Therapeutics Announces Results of Annual and Special Shareholder MeetingVBL Therapeutics shareholders approved its merger with Notable Labs at the annual and special meeting on October 12, 2023, with over 98% voting in favor. The merger is expected to close on or around October 16, 2023, and the combined company will trade under the ticker NTBL on Nasdaq.GlobeNewswireVBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder MeetingVBL Therapeutics reminded shareholders to vote on its proposed merger with Notable Labs at the annual and special meeting on October 12, 2023. The merger, expected to close within days after approval, would rename VBL as Notable Labs, Ltd. and trade under the symbol NTBL.GlobeNewswireVBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SECVBL Therapeutics announced that its S-4 registration statement for the proposed merger with Notable Labs was declared effective by the SEC. The merger is expected to close in mid-October 2023, subject to shareholder approval, with the combined company to be listed on Nasdaq.GlobeNewswireVBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateVBL Therapeutics reported a Q2 2023 net loss of $0.9 million, down from $9.4 million in the prior year, and held $24.3 million in cash. The company expects to close its merger with Notable in late September or October 2023, subject to SEC approval and shareholder votes.